尿可溶性CD163:狼疮性肾炎活动性的新型无创生物标志物
本研究在墨西哥及美国队列中评估尿CD163与狼疮性肾炎活动性的关系。尿CD163在活动性狼疮性肾炎患者中显著升高,与临床严重度、组织学分级及活动指数相关,且随治疗反应动态变化。尿CD163<370 ng/mmol可预测12个月完全肾脏缓解,并与重复活检组织学活动指数高度一致。
要点
- 尿CD163水平在活动性狼疮性肾炎中显著升高,并与组织学活动指数相关。
- 尿CD163<370 ng/mmol预测12个月完全肾脏缓解敏感性及特异性均>87%。
- 尿CD163<370或>370 ng/mmol与重复活检活动指数≤1或>1完全一致(κ=1.0)。
核心结论
- 尿CD163反映狼疮性肾炎的组织学炎症,是随疾病活动及治疗动态变化的有前景的活动性生物标志物。
研究设计与样本
- 研究测量了墨西哥队列、美国横断面及纵向队列中狼疮性肾炎 flare 患者的尿CD163。
- 对墨西哥及美国纵向队列部分患者进行flare治疗期间系列尿CD163测量,并评估12个月治疗反应。
- 在19例墨西哥队列重复肾活检患者中评估尿CD163与组织学活动的一致性。
主要发现
- 活动性狼疮性肾炎患者尿CD163显著高于活动性肾外SLE、非活动性SLE及其他肾小球疾病患者。
- 尿CD163与疾病临床严重度、组织学分级及组织学活动指数相关。
- 尿CD163从flare前6个月至flare升高,完全及部分缓解者逐渐下降,无缓解者持续升高。
- 6个月时尿CD163<370 ng/mmol预测12个月完全肾脏缓解敏感性>87%、特异性>87%。
- 重复活检中尿CD163<370 ng/mmol或>370 ng/mmol与组织学活动指数≤1或>1完全一致(κ=1.0)。
关键数值与推荐
- 尿CD163<370 ng/mmol预测12个月完全肾脏缓解敏感性>87%、特异性>87%。
- 尿CD163<370 ng/mmol或>370 ng/mmol与重复活检组织学活动指数≤1或>1完全一致(κ=1.0)。
临床怎么用
- 尿CD163可作为无创标志物辅助鉴别狼疮性肾炎活动性炎症与慢性损伤。
- 系列监测尿CD163有助于评估治疗反应及预测12个月完全肾脏缓解。
- 6个月时尿CD163<370 ng/mmol提示完全肾脏缓解可能性高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical distinction between patients with lupus nephritis who have active inflammation or chronic kidney damage is challenging. Studies have shown soluble CD163, which derives from cleavage of the CD163 M2c macrophage receptor and can be quantified in urine, correlates with active lupus nephritis. METHODS: We measured urine CD163 at lupus nephritis flares in patients from a Mexican cohort and cross-sectional and longitudinal United States cohorts. We also performed serial urine CD163 measurements during the treatment of flares in a subset of patients from the Mexican and longitudinal United States cohorts, and assessed response to therapy at 12 months. In addition, we evaluated urinary CD163 agreement with histologic activity in 19 patients from the Mexican cohort who had repeated kidney biopsies on follow-up. RESULTS: Urinary CD163 levels were significantly higher in patients with active lupus nephritis than in patients with active extrarenal SLE, inactive SLE, and other glomerular diseases, and correlated with disease clinical severity, histologic class, and the histologic activity index. Urinary CD163 increased from 6 months preflare to flare, diminishing progressively in complete and partial responders, whereas it remained elevated in nonresponders. Urinary CD163 <370 ng/mmol at 6 months predicted complete renal response at 12 months with >87% sensitivity and >87% specificity. Urinary CD163 <370 ng/mmol or >370 ng/mmol perfectly agreed (κ=1.0) with a histologic activity index ≤1 or >1 in repeated biopsies, respectively. Evaluation of urinary CD163 in patients with persistent proteinuria at 6 months improved the prediction of who would achieve complete renal response at 12 months. CONCLUSIONS: Urinary CD163 reflects histologic inflammation in lupus nephritis and is a promising activity biomarker that varies over time with lupus nephritis activity and treatment.
引用
- Mejia-Vilet JM, Zhang XL, Cruz C, et al. Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. J Am Soc Nephrol. 2020. PMID: 32300067. doi:10.1681/ASN.2019121285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。